Drug intelligence / Profile preview

GT-007

Development stage: Unknown
Lead developer: Grit Biotechnology
Modality: Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GT-007 is an investigational tumor-infiltrating lymphocyte (TIL) therapy under development by Zhuhai Grit Biotechnology. It is being explored for the treatment of hematologic neoplasms and other cancers. The drug is currently in the discovery phase, and detailed information about its mechanism of action has not been disclosed. TIL therapies generally involve isolating lymphocytes from a patient's tumor, expanding them ex vivo, and reinfusing them to target cancer cells.

Beyond the preview

Go deeper on GT-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT-007.

Explore the full profile